These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 4039590)

  • 1. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics.
    Klotz U; Maier KE; Fischer C; Bauer KH
    Arzneimittelforschung; 1985; 35(3):636-9. PubMed ID: 4039590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE; Schraa CC
    Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man.
    Fischer C; Maier K; Stumpf E; von Gaisberg U; Klotz U
    Eur J Clin Pharmacol; 1983; 25(4):511-5. PubMed ID: 6140167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Aminosalicylic acid for the treatment of inflammatory bowel disease.
    Dew MJ; Evans BK; Rhodes J
    Gastroenterology; 1984 Aug; 87(2):480-1. PubMed ID: 6735091
    [No Abstract]   [Full Text] [Related]  

  • 7. [Local or systemic treatment of inflammatory bowel diseases?].
    Schmassmann A; Halter F
    Ther Umsch; 1993 Feb; 50(2):94-9. PubMed ID: 8096092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
    Christensen LA; Jacobsen BA
    Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
    Robinson MG
    Gastroenterol Clin North Am; 1989 Mar; 18(1):43-50. PubMed ID: 2646221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
    Tromm A; Griga T; May B
    Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
    Sandborn WJ; Hanauer SB; Buch A
    Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady state disposition of 5-aminosalicyclic acid following oral dosing.
    Klotz U; Stracciari GL
    Arzneimittelforschung; 1993 Dec; 43(12):1357-9. PubMed ID: 8141827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
    Hanauer SB; Krawitt EL; Robinson M; Rick GG; Safdi MA
    Am J Gastroenterol; 1993 Sep; 88(9):1343-51. PubMed ID: 8362827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.
    Kreisel W; Wolf LM; Grotz W; Grieshaber M
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):461-8. PubMed ID: 8804875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current therapeutic possibilities in chronic inflammatory intestinal diseases].
    Schölmerich J
    Praxis (Bern 1994); 1995 Jan; 84(2):29-33. PubMed ID: 7839043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical management of patients with difficult-to-treat inflammatory bowel disease.
    van Hogezand RA
    Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1990 Oct; 4(5):497-505. PubMed ID: 2129637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oroileal transit of slow release 5-aminosalicylic acid.
    Goebell H; Klotz U; Nehlsen B; Layer P
    Gut; 1993 May; 34(5):669-75. PubMed ID: 8504969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.